Document is current

Article History

Received: 10 March 2025

Accepted: 3 April 2025

First Online: 14 April 2025

Declarations

:

: The study was approved by the ethics committee of Charité – Universitätsmedizin Berlin (EA4/246/23). Data were kept confidential and were not disclosed unless for study purposes. This study is reported in accordance with the “Strengthening the Reporting of Observational Studies in Epidemiology” (STROBE) statement for cohort studies [48].

: As this was a retrospective analysis, written consent from the participating patients was not required according to local regulations.

: MF reports personal fees from Novartis and Teva. KSL reports personal fees from Organon and Teva. UR reports no personal fees; institutional fees from Amgen, Abbvie, Lilly, Lundbeck, Novartis, Medscape, Pfizer, StreaMedUp, and Teva, and research funding from Novartis. UR is the vice-president of the EHF and associate editor of JHP. BR reports research grants from Lundbeck, Novartis, German Research Foundation, German Migraine and Headache Society, Else Kröne-Fresenius-Stiftung and personal fees from Abbvie/Allergan, Eli Lilly, Lundbeck, Novartis, Organon, Perfood and Teva. BR is an Editorial Board Member of The Journal of Headache and Pain. LHO, MU, JBH, CLH and YS have nothing to disclose.